Use of methotrexate in patients with psoriatic arthritis

Clinical and Experimental Rheumatology

Volumn 28, Issue 5 SUPPL. 61, 2010, Pages

  Ceponis, A ^a   Kavanaugh, A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Disease modifying drugs; Methotrexate; Psoriatic arthritis

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD68 ANTIGEN; CD8 ANTIGEN; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FOLIC ACID; INFLIXIMAB; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 12P35; INTERLEUKIN 12P40; INTERLEUKIN 8; L SELECTIN; LEFLUNOMIDE; MESSENGER RNA; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR INHIBITOR; C REACTIVE PROTEIN; PLACEBO; RHEUMATOID FACTOR; STROMELYSIN;

ALOPECIA; ARTICLE; AXIAL DISEASE; CELL INFILTRATION; CLINICAL PRACTICE; COMORBIDITY; CYTOKINE RELEASE; DACTYLITIS; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENTHESITIS; ERYTHROCYTE SEDIMENTATION RATE; GASTROINTESTINAL INTOLERANCE; GASTROINTESTINAL MANIFESTATION; GENE EXPRESSION; HUMAN; IMMUNOPATHOGENESIS; IRITIS; JOINT ASPIRATION; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER NECROSIS; LIVER TOXICITY; MOUTH ULCER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; STOMATITIS; SYNOVIAL FLUID; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; UVEITIS; AMINO ACID METABOLISM; CLINICAL FEATURE; DISEASE COURSE; DISEASE SEVERITY; DRUG POTENTIATION; EVIDENCE BASED MEDICINE; GENETIC VARIABILITY; HEALTH ASSESSMENT QUESTIONNAIRE; OBSERVATIONAL STUDY; RANGE OF MOTION; VISUAL ANALOG SCALE;

ANTI-INFLAMMATORY AGENTS; ARTHRITIS, PSORIATIC; BIOLOGICAL PRODUCTS; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; HUMANS; METHOTREXATE; RISK ASSESSMENT; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78650529461     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. GELFAND J, GLADMAN D, MEASE P et al.: Epidemiology of psoriatic arthritis in the United States population. J Am Acad Dermatol 2005;53:573.
2. MOLL JM, WRIGHT V: Psoriatic arthritis. Semin Arthritis Rheum 1973;3:55-78.
3. TAYLOR W, GLADMAN D, HELLIWELL P et al.; CASPAR STUDY GROUP: Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006;54:2665-73.
4. VANDER CRUYSSEN B, HOFFMAN IE, ZMIERCZAK H et al.: Anti-citrullinated peptide antibodies may occur in patients with psoriatic arthritis. Ann Rheum Dis 2005;64:1145-9.
5. KANE D, STATFFORD L, BRESNIHAN B, FITZGERALD O: A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology (Oxford) 2003;42:1460-8.
6. HELLIWELL PS, TAYLOR W, for the CASPAR STUDY GROUP: Treatment of psoriatic arthritis and rheumatoid arthritis with disease modifying drugs - comparison of drugs and adverse reactions. J Rheumatol 2008;35:472-6.
7. KANE D, GOGARTY M, O'LEARY J et al.: Reduction of synovial sublining layer inflammation and proinflammatory cytokine expression in psoriatic arthritis treated with methotrexate. Arthritis Rheum 2004;50:3286-95.
8. CEPONIS A, KONTTINEN YT, MACKEVICIUS Z et al.: Aberrant vascularity and von Willebrand factor distribution in inflamed synovial membrane. J Rheumatol 1996;23:1880-6.
9. CEPONIS A, KONTTINEN YT, IMAI S et al.: Synovial lining, endothelial and inflammatory mononuclear cell proliferation in synovial membranes in psoriatic and reactive arthritis: a comparative quantitative morphometric study. Br J Rheumatol 1998;37:170-8.
10. CEPONIS A, HIETANEN J, TAMULAITIENE M et al.: A comparative quantitative morphometric study of cell apoptosis in synovial membranes in psoriatic, reactive and rheumatoid arthritis. Rheumatology (Oxford) 1999;38:431-40.
11. KRUITHOF E, BAETEN D, DE RYCKE L et al.: Synovial histopathology of psoriatic arthritis, both oligo-and polyarticular, resembles spondyloarthropathy more than it does rheumatoid arthritis. Arthritis Res Ther 2005;7: R569-80.
12. KAVANAUGH AF, RITCHLIN CT, THE GRAPPA Treatment Guideline Committee: Systematic review of treatments for psoriatic arthritis: an evidence based approach and basis for treatment guidelines. J Rheumatol 2006;33:1417-21.
13. RITCHLIN CT, KAVANAUGH A, GLADMAN DD et al.; AND GROUP FOR RESEARCH AND ASSESSMENT OF PSORIASIS AND PSORIATIC ARTHRITIS (GRAPPA): Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2009;68:1387-94.
14. CEPONIS A, KAVANAUGH A: Treatment of psoriatic arthritis with biological agents. Semin Cutan Med Surg 2010;29:56-62.
15. GUBNER R, AUGUST S, GINSBERG V: Therapeutic suppression of tissue reactivity. II. Effect of aminopterin in rheumatoid arthritis and psoriasis. Am J Med Sci 1951;221:176-82.
16. O'BRIAN WM, VAN SCOTT EI, BLACK RL, EISEN AZ, BUNIM JJ: Clinical trial of aminopterin (Methotrexate) in psoriatic and rheumatoid arthritis (Preliminary Report). Arthritis Rheum 1962;5:312.
17. BLACK RL, O'BRIEN WM, VANSCOTT EJ, AUERBACH R, EISEN AZ, BUNIM JJ: Methotrexate therapy in psoriatic arthritis: doubleblind study on 21 patients. JAMA 1964;189:743-7.
18. WILLKENS RF, WILLIAMS HJ, WARD JR et al.: Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum 1984;27:376-81.
19. SCARPA R, PELUSO R, ATTENO M et al.: The effectiveness of a traditional therapeutical approach in early psoriatic arthritis: results of a pilot randomised 6-month trial with methotrexate. Clin Rheumatol 2008;27:823-6.
20. KINGSLEY GH, PACKHAM JC, MCHUGH NJ et al.: Methotrexate is not disease modifying in psoriatic arthritis: a new treatment paradigm is required. Annual meeting of the British Society for Rheumatology, 2010.
21. KRAGBALLE K, ZACHARIAE E, ZACHARIAE H: Methotrexate in psoriatic arthritis: a retrospective study. Acta Derm Venereol 1983;63:165-7.
22. ZACHARIAE H, ZACHARIAE E: Methotrexate treatment of psoriatic arthritis. Acta Derm Venereol 1987;67:270-3.
23. ESPINOZA LR, ZAKRAOUI L, ESPINOZA CG et al.: Psoriatic arthritis: clinical response and side effects to methotrexate therapy. J Rheumatol 1992;19:872-7.
24. RANZA R, MARCHESONI A, ROSSETTI A, TOSI S, GIBELLI E: Methotrexate in psoriatic polyarthritis. J Rheumatol 1993;20:1804-5.
25. ABU-SHAKRA M, GLADMAN DD, THORNE JC et al.: Longterm methotrexate therapy in psoriatic arthritis: clinical and radiological outcome. J Rheumatol 1995;22:241-5.
26. KANE D, GOGARTY M, OTEARY J et al.: Reduction of synovial sublining layer inflammation and proinflammatory cytokine expression in psoriatic arthritis treated with methotrexate. Arthritis Rheum 2004;50:3286-95.
27. CHANDRAN V, SCHENTAG CT, GLADMAN DD: Reappraisal of the effectiveness of methotrexate in psoriatic arthritis: results from a longitudinal observational cohort. J Rheumatol 2008;35:469-471.
28. LIE E, VAN DER HEIJDE D, UHLIG T et al.: Effectiveness and retention rates of methotrexate in psoriatic arthritis in comparison with methotrexate-treated patients with rheumatoid arthritis. Ann Rheum Dis 2010;69:671-6.
29. RICCI M, DE MARCO G, DESIATI F et al.: A. Long-term survival of methotrexate in psoriatic arthritis. Reumatismo (Italian), 2009;61:125-31.
30. LACAILLLE D, STEIN HB, RABOUD J, KLINKHOFF AV: Longterm therapy of psoriatic arthritis: intramuscular gold or methotrexate? J Rheumatol 2000;27:1922-7.
31. SPADARO A, RICCIERI V, SILI-SCAVALLI A et al.: Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one-year prospective study. Clin Exp Rheumatol 1995;13:589-93.
32. MALESCI D, TIRRI R, BUONO R, LA MONTAGNA G: Lefiunomide in psoriatic arthritis: a retrospective study of discontinuation rate in daily clinical practice compared with methotrexate. Clin Exp Rheumatol 2007;25:881-4.
33. KALTWASSER JP, NASH P, GLADMAN D et al. FOR THE TREATMENT PSORIATIC ARTHRITIS STUDY GROUP: Efficacy and safety of lefiunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 2004;50:1939-50.
34. RAFFAYOVA H, KUNGUROV N, KUBANOVA A et al.: ACR 2009; Philadelphia, #1256, #1780.
35. CURTIS JR, BEUKELMAN T, ONOFREI A et al.: Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or lefiunomide. Ann Rheum Dis 2010;69:43-7.
36. KAVANAUGH A, GREENBER JD, LEE SJ et al. Incidence of elevated liver enzymes (LFTs) in psoriatic arthritis (PsA) patients: effect of TNF-inhibitors (TNF-I). EULAR 2010; SAT0282.
37. GRISMER LE, GILL SA, HARRIS MD: Liver biopsy in psoriatic arthritis to detect methotrexate hepatotoxicity. J Clin Rheumatol 2001;7:224-7.
38. ALARCON GS: Psoriatic arthritis, methotrexate, and liver toxicity. J Clin Rheumatol 2001;7:213-4.
39. TAYLOR WJ, KORENDOWYCH E, NASH P et al.: Drug use and toxicity in psoriatic disease: focus on methotrexate. J Rheumatol 2008;35:1454-7.
40. LINDSAY K, GOUGH A: Psoriatic arthritis, methotrexate and the liver-are rheumatologists putting their patients at risk? Rheumatology (Oxford) 2008;47:939-41.
41. AMITAL H, ARNSON Y, CHODICK G, SHALEV V: Hepatotoxicity rates do not differ in patients with rheumatoid arthritis and psoriasis treated with methotrexate. Rheumatology (Oxford) 2009;48:1107-10.
42. ROSENBERG P, URWITZ H, JOHANNESSON A et al.: Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment. J Hepatol 2007;46:995-8.
43. GOTTLIEB AB, DANN F, MENTER A: Psoriasis and the metabolic syndrome. J Drugs Dermatol 2008;7:563-72.
44. GOTTLIEB AB, DANN F: Comorbidities in patients with psoriasis. Am J Med 2009;122:1150.